Acrivon Therapeutics Inc
Company Profile
Business description
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Contact
480 Arsenal Way
Suite 100
WatertownMA02472
USAT: +1 617 207-8979
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
76
Stocks News & Analysis
stocks
ASX rare earths play looks to expand production
stocks
Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation
stocks
The 10 best US companies to invest in now
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.50 | 44.30 | 0.50% |
| CAC 40 | 7,870.40 | 36.30 | 0.46% |
| DAX 40 | 25,464.37 | 210.16 | 0.83% |
| Dow JONES (US) | 51,647.96 | 380.06 | 0.74% |
| FTSE 100 | 10,540.26 | 42.32 | 0.40% |
| HKSE | 24,280.56 | 240.22 | 1.00% |
| NASDAQ | 27,721.67 | 244.36 | 0.89% |
| Nikkei 225 | 70,683.98 | 737.12 | 1.05% |
| NZX 50 Index | 13,700.12 | 1.10 | 0.01% |
| S&P 500 | 7,842.18 | 68.23 | 0.88% |
| S&P/ASX 200 | 8,735.70 | 49.30 | 0.57% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |